No profile data available.
Biomea Fusion, Inc. (BMEA) is a healthcare company in the blood sugar management drugs industry, based in San Carlos, United States, with about 37 full-time employees.
It reported revenue of $0 for fiscal year 2025, and net income of -$61.80 million. Its market capitalization was $102.93 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a clinical-stage diabetes and obesity medicines company, focuses on the discovery and development of oral drugs to treat patients with diabetes and obesity.
Biomea Fusion reported $0 in revenue for fiscal year 2025.
$102.93 million as of October 9, 2026.
Listed companies of a similar size in the same industry (blood sugar management drugs) include Eli Lilly and Company (LLY), Novo Nordisk A/S (NVO), Oramed Pharmaceuticals Inc. (ORMP), Vicapsys Life Sciences, Inc. (VICP).